Reglan Tardive Dyskinesia Settlement: Claim Valuation Factors Overview

Latest update (2025-07)

FDA enforcement record (Ongoing): Presence of foreign tablets/capsules. [source]

From General Health Information to Targeted Risk Assessment

For decades, general health and science information has served as a foundational resource for public understanding of medication risks and therapeutic benefits. This broad educational context has empowered individuals to engage with medical guidance, recognize potential side effects, and make informed decisions about treatment options. Within this legacy framework, the focus remained on population-level awareness rather than specific exposure pathways or occupational considerations. As the scope of health information evolves, a natural progression emerges from general awareness to more targeted risk assessment. In the context of mass production environments, where repetitive processes and chemical exposures are routine, the transition from general health literacy to occupational exposure concern becomes particularly relevant. Workers in manufacturing settings may encounter substances or conditions that amplify medication-related risks, necessitating a shift in focus from broad public education to workplace-specific hazard identification. This pivot acknowledges that while general health information provides essential baseline knowledge, occupational settings introduce unique variables that can alter risk profiles. The transition from a general health context to one centered on occupational exposure requires careful consideration of how workplace factors interact with pharmaceutical agents, without delving into specific disease mechanisms. This approach maintains the neutral, academic tone of the legacy framework while expanding its practical application to mass production environments where exposure concerns demand heightened attention.

Find Out If You Qualify for Compensation →

Reglan and Tardive Dyskinesia: Medical Evidence and Risk Context

Reglan (metoclopramide) is associated with tardive dyskinesia (TD), a potentially irreversible movement disorder. The FDA-approved labeling for Reglan includes a boxed warning stating that metoclopramide can cause TD, and that the risk increases with duration of treatment and total cumulative dosage (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The labeling further notes that Reglan is contraindicated in patients with a history of TD, and that the drug should be used for the shortest duration necessary, with periodic reassessment of continued need (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). For patients with symptomatic, documented gastroesophageal reflux, the maximum recommended treatment duration is 12 weeks; for diabetic gastroparesis, total treatment beyond 12 weeks should be avoided unless longer use is unavoidable, in which case routine monitoring for TD signs and symptoms is advised (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Clinical presentation of TD includes involuntary, often disfiguring movements of the face or tongue, and sometimes the trunk or extremities (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The condition may be irreversible even after drug discontinuation. The labeling also warns that metoclopramide may suppress or partially suppress signs of TD, potentially delaying diagnosis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Other extrapyramidal symptoms and neuroleptic malignant syndrome are also possible, and concomitant use of other drugs known to cause these effects should be avoided (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).

Epidemiological Data and Risk Factors

Epidemiological data on TD incidence with metoclopramide have varied. A real-world study using the MarketScan Research database (2011-2020) examined TD incidence in adults with at least 12 months of medical and pharmacy benefits, comparing metoclopramide-treated gastroparesis patients, untreated patients, and the general population (https://pubmed.ncbi.nlm.nih.gov/41588797/). This study aimed to reassess risk estimates based on older studies that reported incidence rates from 1% to 15% (https://pubmed.ncbi.nlm.nih.gov/41588797/). Another analysis, based on a literature search of PubMed, Google Scholar, and cross-references, found that the risk of TD from metoclopramide is low, approximately 0.1% per 1000 patient-years, which is far below the previously estimated 1%-10% risk suggested in treatment guidelines by regulatory authorities (https://pubmed.ncbi.nlm.nih.gov/31050085/). That analysis identified high-risk groups as elderly females, diabetics, patients with liver or kidney failure, and those on concomitant antipsychotic drug therapy, which reduces the threshold for neurological complications (https://pubmed.ncbi.nlm.nih.gov/31050085/).

Claim Valuation Factors for Reglan TD Settlements

From a settlement perspective, claim valuation factors include the adequacy of warnings regarding TD risk. The boxed warning explicitly states the risk and the need for short-term use, but historical prescribing practices may have involved longer durations or inadequate patient monitoring. The timeline between exposure and documented harm is critical: TD can develop after months or years of metoclopramide use, and the labeling emphasizes immediate discontinuation if signs or symptoms occur (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). For affected patients, settlement considerations may involve the severity and irreversibility of TD, the duration and dosage of Reglan exposure, and whether the prescribing physician followed recommended monitoring and duration guidelines. The presence of known risk factors, such as diabetes or advanced age, may also influence claim valuation. Overall, the evidence underscores that while the absolute risk of TD from metoclopramide may be lower than older estimates, the condition remains serious and potentially permanent, warranting careful adherence to prescribing limits and patient monitoring.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.

Frequently Asked Questions

What is the FDA boxed warning for Reglan regarding tardive dyskinesia?

The FDA-approved labeling for Reglan includes a boxed warning stating that metoclopramide can cause tardive dyskinesia (TD), a potentially irreversible movement disorder. The risk increases with duration of treatment and total cumulative dosage. Reglan is contraindicated in patients with a history of TD, and the drug should be used for the shortest duration necessary, with periodic reassessment of continued need (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).

What are the key factors in valuing a Reglan tardive dyskinesia claim?

Claim valuation factors include the adequacy of warnings regarding TD risk, the timeline between exposure and documented harm, severity and irreversibility of TD, duration and dosage of Reglan exposure, whether the prescribing physician followed recommended monitoring and duration guidelines, and the presence of known risk factors such as diabetes or advanced age (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Reglan exposure and a confirmed Tardive Dyskinesia diagnosis may request an independent eligibility review. [Begin Assessment]

References

Find Out If You Qualify for Compensation

Statutes of limitations can limit the time you have to file a claim. A records screening is free and confidential.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.